Trial Search Results

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

This clinical trial studies how well 18F-fluoromisonidazole ([18F]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor. [18F]FMISO is a type of radioimaging agent that binds to large molecules in tumor cells that have a low level of oxygen, and the radiation given off by [18F]FMISO is picked up by a PET scan and this may help researchers learn whether changes occur in the tumors after treatment, which can help decide how well the treatment worked earlier than is currently possible

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Drug: 18F-Fluoromisonidazole
  • Procedure: Arterial Embolization
  • Diagnostic Test: Computed Tomography
  • Diagnostic Test: Positron Emission Tomography


Phase 2


Inclusion Criteria:

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

   - Histopathologic or imaging and clinical features of tumor(s) diagnostic for
   hepatocellular carcinoma with at least one tumor >= 1.5 cm; imaging features
   diagnostic for hepatocellular carcinoma will be defined as Liver Imaging Reporting and
   Data System (LIRADS) 4 or greater

   - Total bilirubin < 3.0

   - Child Pugh A or B

   - Tumor amenable to transcatheter arterial embolization

   - Able to provide informed consent

Exclusion Criteria:

   - Uncontrolled large ascites

   - Main or segmental portal vein thrombosis

   - Locoregional treatment of hepatocellular carcinoma within the prior 3 months or
   chemotherapy within the previous 3 months

   - Inability or contraindication to undergo transcatheter arterial embolization

   - Inability to lay flat for at least 2 consecutive hours

   - Severe acute illness

   - Uncontrolled chronic illness such as hypertension, diabetes, or heart failure

   - Contraindication to CT or MRI contrast

   - Pregnancy

Ages Eligible for Study

19 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting